Vaxart, Inc. - Common Stock (VXRT) Financials
VXRT Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 91.8 million | 34.0 million |
2023-09-30 | 105.6 million | 34.1 million |
2023-06-30 | 122.7 million | 37.6 million |
2023-03-31 | 129.9 million | 40.1 million |
VXRT Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -13.4 million | 3.7 million |
2023-09-30 | -15.3 million | 3.8 million |
2023-06-30 | -17.9 million | 3.9 million |
2023-03-31 | -25.7 million | 2.6 million |
VXRT Net Income
No data available :(
VXRT Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | - | - | 20.1 million |
2023-09-30 | 52.2 million | - | 20.5 million |
2023-06-30 | 67.9 million | - | 21.0 million |
2023-03-31 | 71.8 million | - | 21.5 million |
VXRT Shares Outstanding
VXRT Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | - | 14.7 million | 5.4 million | - |
2023-09-30 | 282000 | 15.0 million | 4.9 million | - |
2023-06-30 | 454000 | 18.8 million | 5.6 million | - |
2023-03-31 | 1.2 million | 19.6 million | 6.6 million | - |
VXRT Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 6.6 million | - |
2023-09-30 | 446000 | 15.0 million |
2023-06-30 | 1.4 million | - |
2023-03-31 | 675000 | - |
VXRT
Price: $0.71
52 week price:
Earnings Per Share: -0.57 USD
P/E Ratio: -1.87
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Volume: 1.0 million
Ebitda: -2.9 millionMarket Capitalization: 154.5 million